Media, page-662

Just have come across this article.
The whole writing is just plain flawed.
He did not tell you that the comparison of TACTI002 VS Keynote-048 was actually 2nd line vs 1st line, and yet TACTI002 outperformed.
More importantly, talking about the Cetuximab plus chemo was good enough?
Remind you all from my previous number comparisons, on EFTI plus Keytruda in TACTI002, there is a very strong PD-L1 level dependent benefit shown, and this is chemo FREE! Such benefit is not able to achieve with any current treatment scheme. (Highlighted below)


And then saying in the 2nd line to 2nd line comparison to Keynote-040, the OS data was not so materially different.
The numbers are again highlighted here. Obviously, the journalist's capability to read paper is some what limited.